Influence of the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-1) trial on the use of thrombolytics in Germany. ALKK Study Group. Arbeitsgemeinschaft der Leitenden Kardiologischen Krankenhausärtze

R Zahn; J Rustige; A Koch; R Schiele; U Burczyk; S Schuster; D Harmjanz; D Boppert; M Gottwik; K L Neuhaus; J Senges

doi:10.1016/s0002-9149(97)00677-2

Influence of the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-1) trial on the use of thrombolytics in Germany. ALKK Study Group. Arbeitsgemeinschaft der Leitenden Kardiologischen Krankenhausärtze

Am J Cardiol. 1997 Nov 15;80(10):1339-43. doi: 10.1016/s0002-9149(97)00677-2.

Authors

R Zahn¹, J Rustige, A Koch, R Schiele, U Burczyk, S Schuster, D Harmjanz, D Boppert, M Gottwik, K L Neuhaus, J Senges

Affiliation

¹ Herzzentrum Ludwigshafen, Kardiologie, Germany.

PMID: 9388110
DOI: 10.1016/s0002-9149(97)00677-2

Abstract

Our results show significant and independent influence of the GUSTO-1 trial on the use of recombinant tissue plasminogen activator in acute myocardial infarction in Germany. This influence started soon after the publication of the trial and was not restricted to subgroups who benefitted most from recombinant tissue plasminogen activator.

Publication types

Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Clinical Trials as Topic
Diffusion of Innovation
Female
Fibrinolytic Agents / therapeutic use*
Germany
Humans
Male
Middle Aged
Myocardial Infarction / drug therapy*
Prospective Studies
Streptokinase / therapeutic use
Thrombolytic Therapy / statistics & numerical data*
Tissue Plasminogen Activator / therapeutic use*

Substances

Fibrinolytic Agents
Streptokinase
Tissue Plasminogen Activator